Alnylam’s stock surges as heart drug vies with a Pfizer blockbuster
Alnylam Pharmaceuticals’ stock jumped nearly 40% premarket on Monday after the company released results of a late-stage trial for a heart drug that analysts see competing with a key Pfizer treatment.
Alnylam Pharmaceuticals’ stock jumped nearly 40% premarket on Monday after the company released results of a late-stage trial for a heart drug that analysts see competing with a key Pfizer treatment.
